NASDAQ: IONS
Ionis Pharmaceuticals Inc Stock

$43.78+0.93 (+2.17%)
Updated Aug 15, 2025
IONS Price
$43.78
Fair Value Price
N/A
Market Cap
$6.98B
52 Week Low
$23.95
52 Week High
$50.43
P/E
-24.88x
P/B
11.05x
P/S
6.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$944.05M
Earnings
-$268.22M
Gross Margin
98.9%
Operating Margin
-19.4%
Profit Margin
-28.4%
Debt to Equity
3.73
Operating Cash Flow
-$231M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IONS Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IONS's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
IONS
Ranked
#38 of 482

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important IONS news, forecast changes, insider trades & much more!

IONS News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IONS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IONS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IONS is poor value based on its book value relative to its share price (11.05x), compared to the US Biotechnology industry average (4.5x)
P/B vs Industry Valuation
IONS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IONS due diligence checks available for Premium users.

Valuation

IONS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-24.88x
Industry
-120.52x
Market
35.99x

IONS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
11.05x
Industry
4.5x
IONS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IONS's financial health

Profit margin

Revenue
$452.0M
Net Income
$123.6M
Profit Margin
27.3%
IONS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IONS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.0B
Liabilities
$2.4B
Debt to equity
3.73
IONS's short-term assets ($2.58B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IONS's short-term assets ($2.58B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IONS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IONS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$151.3M
Investing
-$120.1M
Financing
$1.2M
IONS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IONS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IONSB$6.98B+2.17%-24.88x11.05x
LEGNC$6.92B-0.56%-21.07x6.68x
JAZZC$7.14B+0.94%-17.76x1.93x
RVMDF$6.79B+0.83%-8.05x3.64x
NNNNC$7.24B+1.54%909.11x421.37x

Ionis Pharmaceuticals Stock FAQ

What is Ionis Pharmaceuticals's quote symbol?

(NASDAQ: IONS) Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol IONS. Ionis Pharmaceuticals stock quotes can also be displayed as NASDAQ: IONS.

If you're new to stock investing, here's how to buy Ionis Pharmaceuticals stock.

What is the 52 week high and low for Ionis Pharmaceuticals (NASDAQ: IONS)?

(NASDAQ: IONS) Ionis Pharmaceuticals's 52-week high was $50.43, and its 52-week low was $23.95. It is currently -13.19% from its 52-week high and 82.8% from its 52-week low.

How much is Ionis Pharmaceuticals stock worth today?

(NASDAQ: IONS) Ionis Pharmaceuticals currently has 159,391,229 outstanding shares. With Ionis Pharmaceuticals stock trading at $43.78 per share, the total value of Ionis Pharmaceuticals stock (market capitalization) is $6.98B.

Ionis Pharmaceuticals stock was originally listed at a price of $12.31 in Dec 31, 1997. If you had invested in Ionis Pharmaceuticals stock at $12.31, your return over the last 27 years would have been 255.56%, for an annualized return of 4.81% (not including any dividends or dividend reinvestments).

How much is Ionis Pharmaceuticals's stock price per share?

(NASDAQ: IONS) Ionis Pharmaceuticals stock price per share is $43.78 today (as of Aug 15, 2025).

What is Ionis Pharmaceuticals's Market Cap?

(NASDAQ: IONS) Ionis Pharmaceuticals's market cap is $6.98B, as of Aug 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ionis Pharmaceuticals's market cap is calculated by multiplying IONS's current stock price of $43.78 by IONS's total outstanding shares of 159,391,229.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.